Epirus Biopharmaceuticals Inc (EPRS) was Downgraded by Wedbush to ” Neutral” and the brokerage firm has set the Price Target at $2. Earlier the firm had a rating of “Outperform ” on the company shares. Wedbush advised their investors in a research report released on May 11, 2016.
Many Wall Street Analysts have commented on Epirus Biopharmaceuticals Inc. Shares were Reiterated by Wedbush on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 11 from a previous price target of $16 .
Epirus Biopharmaceuticals Inc closed down -1.64 points or -60.29% at $1.08 with 16,10,474 shares getting traded on Tuesday. Post opening the session at $1.86, the shares hit an intraday low of $1.07 and an intraday high of $2 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Dec 22, 2015, Robert Ticktin (General Counsel) purchased 3,000 shares at $3.72 per share price. According to the SEC, on Dec 21, 2015, Aurentz Vincent (Chief Business Officer) purchased 2,200 shares at $3.43 per share price. On Dec 17, 2015, Amit Munshi (CEO) purchased 8,270 shares at $2.80 per share price, according to the Form-4 filing with the securities and exchange commission.
EPIRUS Biopharmaceuticals Inc. (Epirus) is a commercial-stage biopharmaceutical company. The Company is engaged in developing manufacturing and commercializing biosimilar therapeutics (biosimilars). The Company has a pipeline of operationally synergistic monoclonal antibodies (MAbs) in inflammation and immunology. The Company’s lead product candidate BOW015 is indicated for the treatment of various inflammatory diseases. The Company has launched BOW015 under the brand name Infimab. The Company’s products include BOW015 which contains infliximab; BOW050 which contains adalimumab; BOW070 which contains tocilizumab; BOW080 which contains eculizumab; BOW090 which contains ustekinumab and BOW100 which contains golimumab.